Therapy News and Research

RSS

OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

Oxford Gene Technology, The Molecular Genetics Company, is inviting attendees of the British Society for Genetic Medicine annual conference to its seminar entitled ‘Approaches to tumour screening and therapy stratification: case studies in Non-Small Cell Lung Cancer’ on Monday 22nd September, 13.10-13.50, room 2N.

From Oxford Gene Technology 17 Sep 2014

LABA-ICS combination therapy better than LABAs alone for COPD

Among older adults with chronic obstructive pulmonary disease (COPD), particularly those with asthma, newly prescribed long-acting beta-agonists (LABAs) and inhaled corticosteroid combination therapy, compared with newly prescribed LABAs alone, was associated with a lower risk of death or COPD hospitalization, according to a study in the September 17 issue of JAMA.

17 Sep 2014

EnGeneIC receives award from Cancer Institute NSW for groundbreaking cancer research

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, announced that, together with the Asbestos Disease Research Institute, it has received the 2014 Cancer Institute New South Wales Premier’s Award for Excellence in Translational Cancer Research.

17 Sep 2014

Sphere Medical introduces new Proxima miniaturised blood gas analyser at AAGBI 2014

Sphere Medical, innovator in critical care monitoring and diagnostics equipment, will launch its cutting edge in-line patient dedicated arterial blood gas analyser at the AAGBI Annual Congress 2014, Harrogate, 17-19th September.

17 Sep 2014

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.

17 Sep 2014

Adding common epilepsy drug to morphine can result in better pain control, say IU researchers

Adding a common epilepsy drug to a morphine regimen can result in better pain control with fewer side effects. Moreover, the combination can reduce the dosage of the opioid needed to be effective, according to a team of pain researchers at Indiana University.

17 Sep 2014

State highlights: N.Y. sues drugmaker over Alzheimer's drug switch; Ariz. Republican resigns over Medicaid remarks

New York State's attorney general filed an antitrust lawsuit on Monday seeking to stop a pharmaceutical company from forcing patients with Alzheimer's disease to switch to a new version of a widely used drug. The lawsuit contends that the switch is designed to blunt competition from low-priced generic versions of the medication (Pollack, 9/15).

17 Sep 2014

Novel genetic discovery identifies new avenues for prostate cancer treatment

A genetic discovery out of the University of Pittsburgh School of Medicine is leading to a highly accurate test for aggressive prostate cancer and identifies new avenues for treatment.

17 Sep 2014

ADA Maryland Chapter, WellDoc collaborate to empower patients with type 2 diabetes

The American Diabetes Association (ADA) Maryland Chapter and WellDoc®, a health care behavioral science and technology company, have announced the launch of a collaboration to empower people in Maryland with type 2 diabetes to take control of their diabetes by improving their day-to-day self-management.

16 Sep 2014

Complete analysis of the global stem cell market

BCC Research reveals in its new report, THE GLOBAL MARKET FOR STEM CELLS, the global market for stem cells is expected to grow to nearly $10.6 billion by 2018, with a five-year compound annual growth rate (CAGR) of 13.6%.

16 Sep 2014

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

16 Sep 2014

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

A blood test may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma (ESCC), according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.

16 Sep 2014

RT alone effective in decreasing dysphagia in patients with advanced esophageal cancer

Radiation therapy (RT) alone is as effective in decreasing swallowing complications experienced by advanced esophageal cancer patients as RT combined with chemotherapy, thus allowing patients to forgo chemotherapy, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.

16 Sep 2014

Abbott announces initiation of ABSORB IV heart stent clinical trial

Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent.

16 Sep 2014

Thoracic radiotherapy reduces cancer recurrence in SCLC patients, shows new study

Treating advanced small-cell lung cancer (SCLC) with thoracic (or chest) radiation therapy in addition to standard treatment significantly prolongs long-term survival and reduces cancer recurrence in the chest by almost 50%, according to new research published in The Lancet and being presented simultaneously at ASTRO's 2014 Annual Meeting in San Francisco.

16 Sep 2014

Leaky intestines may cripple bacteria-fighting immune cells in patients with CVID

Leaky intestines may cripple bacteria-fighting immune cells in patients with a rare hereditary disease, according to a study by researchers in Lausanne, Switzerland. The study, published in The Journal of Experimental Medicine, may explain why these patients suffer from recurrent bacterial infections.

16 Sep 2014

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.

16 Sep 2014

State Highlights: Calif. prop 45 ad truth check; Medi-Cal autism coverage

Proposition 45 would give California's elected insurance commissioner the authority to reject excessive health insurance rate hikes, a power the commissioner already wields for auto and homeowners insurance rates. The campaign against it -- for which the insurance industry has so far put up $37.3 million -- is now airing a 60-second radio ad narrated by a nurse named Candy Campbell.

16 Sep 2014

Early-stage Hodgkin's disease patients who receive radiation therapy have better survival rate

Patients with stage I and II Hodgkin's Disease who receive radiation therapy (RT) have a higher 10-year survival rate -- 84 percent compared to 76 percent - than those who do not, according to a study presented by researchers at Icahn School of Medicine at Mount Sinai at the American Society for Radiation Oncology's (ASTRO's) 56th Annual Meeting today.

16 Sep 2014

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development.

16 Sep 2014

Therapy News and Research

OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

LABA-ICS combination therapy better than LABAs alone for COPD

EnGeneIC receives award from Cancer Institute NSW for groundbreaking cancer research

Sphere Medical introduces new Proxima miniaturised blood gas analyser at AAGBI 2014

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

Adding common epilepsy drug to morphine can result in better pain control, say IU researchers

State highlights: N.Y. sues drugmaker over Alzheimer's drug switch; Ariz. Republican resigns over Medicaid remarks

Novel genetic discovery identifies new avenues for prostate cancer treatment

ADA Maryland Chapter, WellDoc collaborate to empower patients with type 2 diabetes

Complete analysis of the global stem cell market

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

RT alone effective in decreasing dysphagia in patients with advanced esophageal cancer

Abbott announces initiation of ABSORB IV heart stent clinical trial

Thoracic radiotherapy reduces cancer recurrence in SCLC patients, shows new study

Leaky intestines may cripple bacteria-fighting immune cells in patients with CVID

Cancer-fighting cocktail shows promising results for advanced cervical cancer

State Highlights: Calif. prop 45 ad truth check; Medi-Cal autism coverage

Early-stage Hodgkin's disease patients who receive radiation therapy have better survival rate

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News